Your browser is no longer supported. Please, upgrade your browser.
Settings
CYTK [NASD]
Cytokinetics, Incorporated
Index- P/E- EPS (ttm)-2.08 Insider Own1.20% Shs Outstand64.52M Perf Week2.24%
Market Cap1.77B Forward P/E- EPS next Y-3.15 Insider Trans-40.58% Shs Float63.82M Perf Month-3.82%
Income-127.30M PEG- EPS next Q-0.59 Inst Own- Short Float15.25% Perf Quarter24.75%
Sales55.80M P/S31.71 EPS this Y6.70% Inst Trans7.82% Short Ratio10.60 Perf Half Y49.79%
Book/sh1.76 P/B14.03 EPS next Y-20.70% ROA-34.00% Target Price30.36 Perf Year76.55%
Cash/sh6.48 P/C3.81 EPS next 5Y15.00% ROE-365.80% 52W Range13.45 - 30.14 Perf YTD18.86%
Dividend- P/FCF- EPS past 5Y-15.30% ROI-37.70% 52W High-18.05% Beta1.36
Dividend %- Quick Ratio15.20 Sales past 5Y14.30% Gross Margin- 52W Low83.64% ATR1.34
Employees184 Current Ratio15.20 Sales Q/Q28.80% Oper. Margin- RSI (14)57.39 Volatility4.78% 5.55%
OptionableYes Debt/Eq0.00 EPS Q/Q-31.40% Profit Margin- Rel Volume0.63 Prev Close24.87
ShortableYes LT Debt/Eq1.20 EarningsFeb 25 AMC Payout- Avg Volume917.72K Price24.70
Recom2.00 SMA203.22% SMA5010.30% SMA20016.64% Volume573,796 Change-0.68%
Mar-12-21Initiated Wolfe Research Outperform $50
Feb-18-21Initiated Barclays Overweight $28
Jan-20-21Reiterated H.C. Wainwright Buy $22 → $41
Oct-29-20Initiated Goldman Neutral $16
Jul-10-20Initiated Raymond James Strong Buy $39
May-05-20Initiated Mizuho Buy $31
Apr-09-20Upgrade Morgan Stanley Equal-Weight → Overweight $25
Sep-21-18Initiated Cantor Fitzgerald Overweight
Sep-10-18Resumed Morgan Stanley Equal-Weight $10
Nov-22-17Reiterated Morgan Stanley Overweight $25 → $17
Nov-22-17Downgrade Needham Strong Buy → Buy $22 → $12
Nov-21-17Reiterated H.C. Wainwright Buy $26 → $17
Jul-31-17Initiated Morgan Stanley Overweight $24
Mar-08-17Initiated Rodman & Renshaw Buy $25
Feb-06-17Upgrade Needham Buy → Strong Buy $17 → $22
Dec-16-16Initiated Cantor Fitzgerald Overweight $21
Jul-28-16Reiterated Needham Buy $15 → $17
Nov-10-15Reiterated FBR Capital Outperform $14 → $24
Nov-09-15Reiterated ROTH Capital Buy $18 → $22
Jul-24-15Reiterated MLV & Co Buy $9 → $14
Apr-12-21 07:30AM  
Apr-05-21 04:00PM  
Apr-02-21 04:00PM  
Apr-01-21 04:00PM  
Mar-18-21 07:30AM  
07:23AM  
Mar-02-21 04:00PM  
Feb-26-21 04:32PM  
07:30AM  
02:30AM  
Feb-25-21 04:00PM  
02:30PM  
Feb-18-21 07:30AM  
02:39AM  
Feb-14-21 01:32PM  
Feb-11-21 04:00PM  
Feb-02-21 07:30AM  
Feb-01-21 04:00PM  
Jan-13-21 07:30AM  
Jan-11-21 07:30AM  
Jan-06-21 04:00PM  
Dec-23-20 07:30AM  
Dec-19-20 02:44PM  
Dec-14-20 07:30AM  
Dec-09-20 07:30AM  
Dec-07-20 07:30AM  
Dec-03-20 07:30AM  
Dec-01-20 04:00PM  
07:30AM  
Nov-29-20 06:44AM  
Nov-24-20 04:00PM  
03:07PM  
Nov-23-20 07:30AM  
Nov-20-20 07:30AM  
Nov-16-20 07:30AM  
07:30AM  
Nov-13-20 11:53AM  
11:35AM  
11:35AM  
Nov-10-20 04:00PM  
Nov-06-20 07:30AM  
06:13AM  
Nov-04-20 10:32PM  
05:15PM  
04:00PM  
02:30PM  
Oct-28-20 12:33PM  
Oct-22-20 12:33PM  
08:43AM  
Oct-21-20 04:00PM  
Oct-13-20 03:24PM  
Oct-09-20 12:46PM  
Oct-08-20 04:13PM  
04:11PM  
10:14AM  
08:30AM  
08:30AM  
Oct-05-20 04:26PM  
04:00PM  
08:48AM  
07:30AM  
Oct-02-20 07:30AM  
Sep-28-20 05:25PM  
Sep-25-20 08:56AM  
Sep-24-20 04:00PM  
07:30AM  
Sep-23-20 07:30AM  
Sep-17-20 07:30AM  
Sep-02-20 04:00PM  
Aug-26-20 07:30AM  
Aug-18-20 07:30AM  
Aug-06-20 04:00PM  
Jul-30-20 12:33PM  
Jul-24-20 08:36AM  
Jul-23-20 04:00PM  
Jul-21-20 04:00PM  
04:00PM  
Jul-20-20 06:39PM  
Jul-16-20 11:32PM  
08:31AM  
Jul-15-20 04:00PM  
07:30AM  
Jul-14-20 07:30AM  
Jul-13-20 07:30AM  
Jul-10-20 10:10AM  
Jul-01-20 04:00PM  
Jun-30-20 11:45AM  
Jun-16-20 09:48PM  
Jun-08-20 04:00PM  
Jun-04-20 11:35AM  
May-27-20 07:30AM  
May-11-20 12:21PM  
May-08-20 08:30AM  
08:30AM  
May-07-20 04:00PM  
04:00PM  
May-06-20 04:00PM  
May-05-20 11:46AM  
May-04-20 05:59PM  
07:58AM  
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a novel fast skeletal muscle troponin activator, which is in Phase II clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops reldesemtiv that is in Phase II clinical trials in patients with chronic obstructive pulmonary disease, and in Phase Ib clinical trials in elderly subjects with limited mobility. In addition, it develops CK-3773274 (CK-274), a novel cardiac myosin inhibitor, which is in Phase II clinical trial for the potential treatment of hypertrophic cardiomyopathy; CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; and CK-3772271 (CK-271), a novel cardiac myosin inhibitor that is in Phase I clinical trial. The company has a strategic alliance with Astellas Pharma Inc. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SMITH SANDFORD DDirectorApr 15Option Exercise9.0810,71497,2486,634Apr 15 06:55 PM
SMITH SANDFORD DDirectorApr 15Sale25.2310,714270,350920Apr 15 06:55 PM
Blum Robert IPresident & CEOApr 12Option Exercise6.305,00031,500361,859Apr 12 05:31 PM
Blum Robert IPresident & CEOApr 12Sale23.565,000117,813356,859Apr 12 05:31 PM
SMITH SANDFORD DDirectorApr 09Option Exercise7.9027,582217,8225,920Apr 12 04:21 PM
SMITH SANDFORD DDirectorApr 09Sale23.9327,582659,990920Apr 12 04:21 PM
Malik Fady IbrahamEVP Research & DevelopmentApr 08Sale23.392,00046,772162,348Apr 08 06:12 PM
HENDERSON JOHN TDirectorApr 01Option Exercise8.643,33328,7978,543Apr 05 06:50 PM
HENDERSON JOHN TDirectorApr 01Sale23.543,33378,4747,410Apr 05 06:50 PM
Blum Robert IPresident & CEOMar 22Option Exercise6.035,00030,170361,293Mar 24 04:13 PM
Blum Robert IPresident & CEOMar 22Sale25.195,000125,972356,859Mar 24 04:13 PM
GAGE L PATRICKDirectorMar 19Option Exercise5.8810,00058,80031,762Mar 19 06:55 PM
GAGE L PATRICKDirectorMar 19Sale24.4510,000244,46821,762Mar 19 06:55 PM
GAGE L PATRICKDirectorMar 12Option Exercise6.7710,33969,99228,768Mar 12 06:58 PM
GAGE L PATRICKDirectorMar 12Sale21.2210,339219,37221,762Mar 12 06:58 PM
Malik Fady IbrahamEVP Research & DevelopmentMar 11Sale19.902,00039,798164,348Mar 11 04:50 PM
Blum Robert IPresident & CEOMar 08Option Exercise6.005,00030,000385,658Mar 08 06:10 PM
Blum Robert IPresident & CEOMar 08Sale19.495,00097,472380,658Mar 08 06:10 PM
Blum Robert IPresident & CEOFeb 26Option Exercise6.005,00030,000339,373Feb 26 06:25 PM
Blum Robert IPresident & CEOFeb 26Sale19.335,00096,651334,373Feb 26 06:25 PM
Blum Robert IPresident & CEOFeb 18Option Exercise9.4283,332784,987382,269Feb 22 05:17 PM
Malik Fady IbrahamEVP Research & DevelopmentFeb 11Sale23.341,63238,097148,809Feb 12 05:37 PM
Blum Robert IPresident & CEOFeb 10Option Exercise6.005,00030,000310,589Feb 12 05:36 PM
Blum Robert IPresident & CEOFeb 10Sale23.885,000119,384305,589Feb 12 05:36 PM
Blum Robert IPresident & CEOJan 29Option Exercise6.005,00030,000310,589Jan 29 05:17 PM
Blum Robert IPresident & CEOJan 29Sale20.345,000101,701305,589Jan 29 05:17 PM
Blum Robert IPresident & CEOJan 20Option Exercise6.005,00030,000310,589Jan 22 04:35 PM
Blum Robert IPresident & CEOJan 20Sale20.415,000102,042305,589Jan 22 04:35 PM
Malik Fady IbrahamEVP Research & DevelopmentJan 14Option Exercise9.4212,500117,750162,324Jan 15 04:35 PM
Malik Fady IbrahamEVP Research & DevelopmentJan 14Sale19.2512,500240,619150,441Jan 15 04:35 PM
Blum Robert IPresident & CEOJan 04Option Exercise6.005,00030,000310,589Jan 04 05:18 PM
Blum Robert IPresident & CEOJan 04Sale20.235,000101,135305,589Jan 04 05:18 PM
HENDERSON JOHN TDirectorDec 31Option Exercise12.9685811,1201,757Dec 31 04:55 PM
HENDERSON JOHN TDirectorDec 31Sale20.3185817,426899Dec 31 04:55 PM
Blum Robert IPresident & CEODec 16Option Exercise6.005,00030,000310,589Dec 18 04:20 PM
Blum Robert IPresident & CEODec 16Sale20.515,000102,551305,589Dec 18 04:20 PM
GAGE L PATRICKDirectorDec 15Option Exercise12.967,71699,99928,520Dec 15 06:09 PM
Cragg DavidSVP Human ResourcesDec 15Option Exercise9.4216,666156,994152,137Dec 17 06:05 PM
GAGE L PATRICKDirectorDec 15Sale21.007,716162,03820,804Dec 15 06:09 PM
Malik Fady IbrahamEVP Research & DevelopmentDec 10Sale20.131,05221,177150,441Dec 10 05:06 PM
BVF PARTNERS L P/ILSee Explanaton of ResponsesDec 09Sale18.00430,9547,757,172463,244Dec 11 06:48 PM
Blum Robert IPresident & CEODec 04Option Exercise6.005,00030,000310,589Dec 04 05:58 PM
Blum Robert IPresident & CEODec 04Sale17.365,00086,798305,589Dec 04 05:58 PM
Blum Robert IPresident & CEONov 23Option Exercise6.005,00030,000309,868Nov 25 04:20 PM
Blum Robert IPresident & CEONov 23Sale15.735,00078,644304,868Nov 25 04:20 PM
Malik Fady IbrahamEVP Research & DevelopmentNov 12Sale17.151,23121,112150,951Nov 16 04:48 PM
Blum Robert IPresident & CEONov 10Option Exercise6.005,00030,000309,868Nov 12 04:59 PM
Blum Robert IPresident & CEONov 10Sale16.505,00082,488304,868Nov 12 04:59 PM
Blum Robert IPresident & CEOOct 29Option Exercise6.005,00030,000309,868Oct 30 04:50 PM
Blum Robert IPresident & CEOOct 29Sale15.155,00075,773304,868Oct 30 04:50 PM
Blum Robert IPresident & CEOOct 13Option Exercise6.005,00030,000309,868Oct 14 04:53 PM
Blum Robert IPresident & CEOOct 13Sale15.945,00079,686304,868Oct 14 04:53 PM
Malik Fady IbrahamEVP Research & DevelopmentOct 08Sale17.451,25821,952152,182Oct 08 05:08 PM
COSTA SANTO JDirectorOct 05Option Exercise9.4515,000141,75015,000Oct 05 05:53 PM
Jaw ChingSVP Finance & CFOOct 05Option Exercise10.0327,500275,70088,300Oct 05 08:23 PM
Kaye Edward M. MDDirectorOct 05Option Exercise7.6120,000152,20020,000Oct 05 08:38 PM
HENDERSON JOHN TDirectorOct 05Option Exercise12.963,00038,8802,399Oct 05 09:03 PM
SMITH SANDFORD DDirectorOct 05Option Exercise7.375,93643,7485,936Oct 05 09:11 PM
PARSHALL B LYNNEDirectorOct 05Option Exercise7.2350,311363,89820,000Oct 06 04:58 PM
Kaye Edward M. MDDirectorOct 05Sale30.0020,000600,0000Oct 05 08:38 PM
Jaw ChingSVP Finance & CFOOct 05Sale30.0027,500825,00073,300Oct 05 08:23 PM
COSTA SANTO JDirectorOct 05Sale30.0015,000450,0000Oct 05 05:53 PM
HENDERSON JOHN TDirectorOct 05Sale29.003,00087,000899Oct 05 09:03 PM
SMITH SANDFORD DDirectorOct 05Sale30.005,936178,0800Oct 05 09:11 PM
PARSHALL B LYNNEDirectorOct 05Sale30.0050,3111,509,3300Oct 06 04:58 PM
Blum Robert IPresident & CEOOct 02Option Exercise6.005,00030,000309,868Oct 02 05:48 PM
Blum Robert IPresident & CEOOct 02Sale22.535,000112,646304,868Oct 02 05:48 PM
Blum Robert IPresident & CEOSep 21Option Exercise6.005,00030,000309,868Sep 21 05:16 PM
Blum Robert IPresident & CEOSep 21Sale20.975,000104,835304,868Sep 21 05:16 PM
Blum Robert IPresident & CEOSep 11Option Exercise6.005,00030,000309,868Sep 11 05:05 PM
Blum Robert IPresident & CEOSep 11Sale22.955,000114,736304,868Sep 11 05:05 PM
Malik Fady IbrahamEVP Research & DevelopmentSep 10Sale22.8599522,736153,440Sep 11 04:37 PM
Blum Robert IPresident & CEOSep 04Option Exercise6.005,00030,000309,868Sep 04 05:29 PM
Blum Robert IPresident & CEOSep 04Sale22.375,000111,854304,868Sep 04 05:29 PM
SCHLOSSBERG MARK ASVP - Legal & General CounselAug 21Option Exercise7.0310,00070,30040,000Aug 21 05:34 PM
Jaw ChingSVP Finance & CFOAug 21Option Exercise7.5425,000188,40088,300Aug 21 05:41 PM
SCHLOSSBERG MARK ASVP - Legal & General CounselAug 21Sale25.0010,000250,00030,000Aug 21 05:34 PM
Jaw ChingSVP Finance & CFOAug 21Sale25.0025,000625,00073,300Aug 21 05:41 PM
Blum Robert IPresident & CEOAug 18Option Exercise6.005,00030,000309,868Aug 20 04:27 PM
Blum Robert IPresident & CEOAug 18Sale23.485,000117,422304,868Aug 20 04:27 PM
Malik Fady IbrahamEVP Research & DevelopmentAug 13Sale21.8559913,088154,435Aug 14 05:16 PM
Blum Robert IPresident & CEOAug 05Option Exercise6.005,00030,000309,868Aug 07 04:39 PM
Blum Robert IPresident & CEOAug 05Sale22.125,000110,621304,868Aug 07 04:39 PM
SCHLOSSBERG MARK ASVP - Legal & General CounselJul 29Option Exercise7.0310,00070,30040,000Jul 30 07:57 PM
SCHLOSSBERG MARK ASVP - Legal & General CounselJul 29Sale23.0710,000230,72830,000Jul 30 07:57 PM
Blum Robert IPresident & CEOJul 28Option Exercise6.005,00030,000309,868Jul 30 07:56 PM
Blum Robert IPresident & CEOJul 28Sale23.775,000118,829304,868Jul 30 07:56 PM
Blum Robert IPresident & CEOJul 16Option Exercise6.005,00030,000309,868Jul 17 05:15 PM
Blum Robert IPresident & CEOJul 16Sale27.365,000136,806304,868Jul 17 05:15 PM
SMITH SANDFORD DDirectorJul 15Option Exercise6.216,66741,4026,667Jul 17 05:14 PM
SMITH SANDFORD DDirectorJul 15Sale29.006,667193,3430Jul 17 05:14 PM
SMITH SANDFORD DDirectorJul 10Option Exercise6.216,66741,4026,667Jul 13 05:34 PM
SMITH SANDFORD DDirectorJul 10Sale28.006,667186,6760Jul 13 05:34 PM
Malik Fady IbrahamEVP Research & DevelopmentJul 09Sale26.961,58742,786155,034Jul 10 08:09 PM
SMITH SANDFORD DDirectorJul 08Option Exercise6.211,4348,9051,434Jul 09 05:37 PM
SMITH SANDFORD DDirectorJul 08Sale27.001,43438,7180Jul 09 05:37 PM
SMITH SANDFORD DDirectorJul 07Option Exercise6.4911,74276,2386,510Jul 09 05:37 PM
SMITH SANDFORD DDirectorJul 07Sale26.4511,742310,5240Jul 09 05:37 PM
Blum Robert IPresident & CEOJul 06Option Exercise6.005,00030,000309,868Jul 08 05:08 PM
Blum Robert IPresident & CEOJul 06Sale24.855,000124,255304,868Jul 08 05:08 PM